Haemodynamic profiles of children with end-stage heart failure

被引:28
|
作者
Chen, Sharon [1 ]
Dykes, John C. [1 ]
McElhinney, Doff B. [1 ]
Gajarski, Robert J. [2 ]
Shin, Andrew Y. [1 ]
Hollander, Seth A. [1 ]
Everitt, Melanie E. [3 ]
Price, Jack F. [4 ]
Thiagarajan, Ravi R. [5 ]
Kindel, Steven J. [6 ]
Rossano, Joseph W. [7 ]
Kaufman, Beth D. [1 ]
May, Lindsay J. [8 ]
Pruitt, Elizabeth [9 ]
Rosenthal, David N. [1 ]
Almond, Christopher S. [1 ]
机构
[1] Stanford Univ, 750 Welch Rd,Suite 305, Palo Alto, CA 94304 USA
[2] Nationwide Childrens Hosp, Columbus, OH USA
[3] Childrens Hosp Colorado, Aurora, CO USA
[4] Texas Childrens Hosp, Houston, TX 77030 USA
[5] Boston Childrens Hosp, Boston, MA USA
[6] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA
[7] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[8] Primary Childrens Med Ctr, Salt Lake City, UT USA
[9] Univ Alabama Birmingham, Pediat Heart Transplant Study Grp, Birmingham, AL USA
关键词
Paediatric heart failure; Haemodynamics; IN-HOSPITAL MORTALITY; MEDICAL-MANAGEMENT; VENOUS CONGESTION; FILLING PRESSURES; TRANSPLANTATION; OUTCOMES; THERAPY; ASSOCIATION; DIAGNOSIS; SOCIETY;
D O I
10.1093/eurheartj/ehx456
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate associations between haemodynamic profiles and symptoms, end-organ function and outcome in children listed for heart transplantation. Methods and results Children <18 years listed for heart transplant between 1993 and 2013 with cardiac catheterization data [pulmonary capillary wedge pressure (PCWP), right atrial pressure (RAP), and cardiac index (CI)] in the Pediatric Heart Transplant Study database were included. Outcomes were New York Heart Association (NYHA)/Ross classification, renal and hepatic dysfunction, and death or clinical deterioration while on waitlist. Among 1059 children analysed, median age was 6.9 years and 46% had dilated cardiomyopathy. Overall, 58% had congestion (PCWP>15mmHg), 28% had severe congestion (PCWP>22mmHg), and 22% low cardiac output (CI<2.2 L/min/m(2)). Twenty-one per cent met the primary outcome of death (9%) or clinical deterioration (12%). In multivariable analysis, worse NYHA/Ross classification was associated with increased PCWP [odds ratio (OR) 1.03, 95% confidence interval (95% CI) 1.01-1.07, P=0.01], renal dysfunction with increased RAP (OR 1.04, 95% CI 1.01-1.08, P=0.007), and hepatic dysfunction with both increased PCWP (OR 1.03, 95% CI 1.01-1.06, P < 0.001) and increased RAP (OR 1.09, 95% CI 1.06-1.12, P < 0.001). There were no associations with low output. Death or clinical deterioration was associated with severe congestion (OR 1.6, 95% CI 1.2-2.2, P=0.002), but not with CI alone. However, children with both low output and severe congestion were at highest risk (OR 1.9, 95% CI 1.1-3.5, P=0.03). Conclusion Congestion is more common than low cardiac output in children with end-stage heart failure and correlates with NYHA/Ross classification and end-organ dysfunction. Children with both congestion and low output have the highest risk of death or clinical deterioration.
引用
收藏
页码:2900 / 2909
页数:10
相关论文
共 50 条
  • [1] Hemodynamic Profiles in Children with End-Stage Fontan Failure Listed for Heart Transplantation
    Asimacopoulos, Eleni P.
    Almond, Christopher S.
    JOURNAL OF CARDIAC FAILURE, 2013, 19 (08) : S90 - S90
  • [2] ICDs in end-stage heart failure
    Pettit, Stephen J.
    Browne, Susan
    Hogg, Karen J.
    Connelly, Derek T.
    Gardner, Roy S.
    May, Carl R.
    Macleod, Una
    Mair, Frances S.
    BMJ SUPPORTIVE & PALLIATIVE CARE, 2012, 2 (02) : 94 - 97
  • [3] Levosimendan in End-Stage Heart Failure
    Yeo, Poh Shuan Daniel
    JACC-HEART FAILURE, 2013, 1 (04) : 365 - 365
  • [4] Dilemmas in end-stage heart failure
    Chen-Scarabelli, Carol
    Saravolatz, Louis
    Hirsh, Benjamin
    Agrawal, Pratik
    Scarabelli, Tiziano M.
    JOURNAL OF GERIATRIC CARDIOLOGY, 2015, 12 (01) : 57 - 65
  • [5] Management of end-stage heart failure
    Moulopoulos, SD
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1996, 19 (06): : 327 - 328
  • [6] Midodrine in end-stage heart failure
    Gonzalez-Cordero, Ariel
    Ortiz-Troche, Stephanie
    Nieves-Rivera, Juan
    Mesa-Pabon, Marcel
    Franqui-Rivera, Hilton
    BMJ SUPPORTIVE & PALLIATIVE CARE, 2023, 13 (E1) : E86 - E87
  • [7] Management of End-Stage Heart Failure
    Murthy, Sandhya
    Lipman, Hannah I.
    PRIMARY CARE, 2011, 38 (02): : 265 - +
  • [8] Hospice and end-stage heart failure
    Huiskes, BL
    Elatre, WA
    Heywood, JT
    CIRCULATION, 2003, 108 (17) : 556 - 556
  • [9] Dilemmas in end-stage heart failure
    Carol ChenScarabelli
    Louis Saravolatz
    Benjamin Hirsh
    Pratik Agrawal
    Tiziano MScarabelli
    Journal of Geriatric Cardiology, 2015, 12 (01) : 57 - 65
  • [10] Telomerase in end-stage heart failure
    Liu, SC
    Wang, SS
    Wu, MZ
    Wu, DC
    Yu, FJ
    Chen, WJ
    Yu, MF
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (01) : 221 - 221